Vast has opened their Reg CF public funding round

Invest now

Breathing is Fundamental

Yet, there are many chronic lung diseases which strain this fundamental act.  At Vast Therapeutics, we are developing breakthrough medicines to treat chronic respiratory diseases so that patients can get back to shopping with friends… back to walking the dog… back to playing with their children or grandchildren… back to traveling the world… BACK TO LIVING.

Over 500 million people worldwide are living with a chronic respiratory disease that, for many, requires a lifetime of care.  Patients experience gradual deterioration in lung function year over year until they reach last resort measures and in too many cases, death.

These life-long battles are being fought with short-term remedies.  Treatments like antibiotics and steroids offer diminishing results over time with significant side effects on the immune system and vital organs.

Vast has a better solution.

A new wave of nitric oxide-based medicines has the potential to restore hope for the hopeless.  Nitric oxide is a natural molecule synthesized by the body that maintains homeostasis of blood flow, neurotransmission, and immune response.  In many respiratory diseases, the ability to make enough nitric oxide is compromised. This leads to failures in the lungs’ ability to transport oxygen, keep inflammation in check, and fight off invading pathogens.

Our technology platform stabilizes nitric oxide, delivers it via inhalation, and releases it in the lung where patients need it the most, targeting the complex mosaic of factors that lead to a decline in quality of life.  We are aiming to ease the burden of care for a wide range of patients, from those with rare orphan diseases like Cystic Fibrosis to those with the highly prevalent Chronic Obstructive Pulmonary Disease (COPD). 

Cystic Fibrosis →